William Blair initiated coverage of Recro Pharma with a rating of Outperform

8-K - Societal CDMO, Inc. (0001588972) (Filer)

10-Q - Societal CDMO, Inc. (0001588972) (Filer)

8-K - Societal CDMO, Inc. (0001588972) (Filer)

8-K - Societal CDMO, Inc. (0001588972) (Filer)

424B5 - Societal CDMO, Inc. (0001588972) (Filer)

8-K - Societal CDMO, Inc. (0001588972) (Filer)

424B5 - Societal CDMO, Inc. (0001588972) (Filer)

8-K - Societal CDMO, Inc. (0001588972) (Filer)

10-Q - Societal CDMO, Inc. (0001588972) (Filer)

8-K - Societal CDMO, Inc. (0001588972) (Filer)

MALVERN, Pa., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Recro (Nasdaq:REPH), a leading contract development and manufacturing organization (CDMO), with integrated solutions for formulation, analytical services, regulatory support, manufacturing and packaging of both commercial and development stage oral solid dose drug products, today announced that David Enloe has been named President, Chief Executive Officer and a member of the Company’s Board of Directors, replacing Gerri Henwood, effective today. Mr. Enloe brings over two decades of executive leadership experience in biotechnology, clinical drug development and GMP manufacturing to Recro, with a proven track record of building and growing CDM

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

4 - Societal CDMO, Inc. (0001588972) (Issuer)

With Expanded Industry Expertise, Enhanced Service Offerings and Bi-Coastal Operations, Company Now Optimally Positioned to Support Customers' Goal of Delivering Impactful Medicines to Society New Ticker (NASDAQ:SCTL) to Initiate Trading on March 22, 2022 SAN DIEGO and GAINESVILLE, Ga., March 21, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it is changing its name to Societal CDMO, Inc. to reflect the corporate transformation that has taken place primarily as a r

Recorded Q4 Revenue of $22.3 Million; Full Year Revenue of $75.4 Million More than Tripled Customer Base in 2021; Significantly Diversified Clientele Grew Organic New Business by 63% in 2021; Grew by 147% Including IriSys Acquisition Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., March 01, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the fourth quarter and year ended December 31, 2021. "At this time last yea

SAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophilization capabilities to its broad suite of CDMO offerings. All construction and equipment installation related to this service expansion has been completed at the company's San Diego facility and final validation and commissioning activities are underway. The company expects that its new automated fill/finish line and lyophilization

SAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (("Recro", NASDAQ:REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market close on Tuesday, March 1, 2022. Recro's management team will host a conference call and audio webcast at 4:30 p.m. ET on Tuesday, March 1, 2022 to discuss the financial results and recent operational highlights. To access the live conference call please dial (844) 243-4691 fr

SAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new formulation development and cGMP manufacturing contract from a key department of the United States government. The contract focuses on supporting clinical development of a topical dermal treatment for the prevention of skin cancer. Under terms of the new, multi-year, $1.5 million contract, the company will formulate, manufacture and supply a topical derma

SAN DIEGO and GAINESVILLE, Ga., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the appointment of Eduardo Uribe as the company's head of quality for Recro San Diego. Mr. Uribe has more than 30 years of experience developing, implementing and managing quality systems within the biotechnology and pharmaceutical industry, including more than a decade in senior leadership positions overseeing quality and compliance at a number of leading CDMOs. In his new role with Rec

SAN DIEGO, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced the addition of new employees to fill open roles in technical operations. Inducement Equity Award In connection with the hiring of these personnel, the compensation committee of Recro's board of directors approved inducement stock option grants to purchase an aggregate of 46,110 shares of Recro's common stock. The option awards were granted pursuant to the NASDAQ inducement grant exception as a component o

SAN DIEGO and GAINESVILLE, Ga., Jan. 03, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will deliver a corporate presentation as part of the H.C. Wainwright BioConnect 2022 Conference. The conference, which will take place January 10-13, 2022, is being conducted with a virtual format. Details for the corporate presentation are as follows: H.C. Wainwright BioConnect 2022 ConferenceConference Dates: January 10-13, 2022Presentat

SAN DIEGO and GAINESVILLE, Ga., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that its chief executive officer, David Enloe, will participate in a fireside chat as part of the Stephens Annual Investment Conference | NASH2021. Details for the fireside chat are as follows: Stephens Annual Investment Conference | NASH2021 Conference dates: December 1 - 3, 2021Presentation details: Recro management will participate in a fireside chat on Friday, December 3, 2021 at

Acquisition of IriSys, Inc. Significantly Expands Customer Pipeline, Facilities and Capabilities Annual Revenue Guidance Increased to between $74 and $76 million Recorded Q3 2021 Revenues of $18.2 Million and Signed Multiple New Business Agreements Further Expanding Customer Base Company to Host Conference Call Today at 4:30 p.m. ET SAN DIEGO and GAINESVILLE, Ga., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. ("Recro"; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported financial results for the third q

According to data from Benzinga Pro, during Q4, Recro Pharma's (NASDAQ:REPH) reported sales totaled $22.30 million. Despite a 32.39% increase in earnings, the company posted a loss of $2.36 million. In Q3, Recro Pharma brought in $18.24 million in sales but lost $3.49 million in earnings. What Is ROCE? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future. In Q4, Recro Pharma posted an R

Recro Pharma (NASDAQ:REPH) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:00 PM. Here's what investors need to know about the announcement. Earnings Recro Pharma beat estimated earnings by 42.86%, reporting an EPS of $-0.04 versus an estimate of $-0.07. Revenue was up $12.39 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.0 which was followed by a 9.57% drop in the share price the next day. Here's a look at Recro Pharma's past performance:   Quarter Q3 2021 Q2 2021 Q1 2021 Q4 2020 EPS Estimate -0.07 -0.11 -0.25 -0.25 EPS Actual -0.07 0.03 -

Recro Pharma (NASDAQ:REPH) reported quarterly losses of $(0.04) per share which beat the analyst consensus estimate of $(0.07) by 42.86 percent. This is a 91.67 percent increase over losses of $(0.48) per share from the same period last year. The company reported quarterly sales of $22.30 million which beat the analyst consensus estimate of $21.41 million by 4.16 percent. This is a 124.96 percent increase over sales of $9.91 million the same period last year.

  Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated to report quarterly loss at $0.63 per share on revenue of $6.74 million. • Quanterix (NASDAQ:QTRX) is likely to report quarterly loss at $0.66 per share on revenue of $28.49 million. • Paya Holdings (NASDAQ:PAYA) is expected to report quarterly earnings at $0.08 per share on revenue of $63.99 million. • APi Gr (NYSE:APG) is likely to report quarterly earnings at $0.26 per share on revenue of $959.69 million. • Pieris Pharmaceuticals (NASDAQ:PIRS) is likely to report quarterly loss at $0.30 per share on revenue of $2.45 milli

Gainers Biomerica (NASDAQ:BMRA) stock increased by 10.2% to $4.95 during Wednesday's after-market session. The market value of their outstanding shares is at $61.9 million. As per the news, the Q2 earnings report came out today. Puma Biotechnology (NASDAQ:PBYI) stock rose 8.39% to $2.84. At the close, Puma Biotechnology's trading volume reached 501.0K shares. This is 72.2% of its average volume over the last 100 days. The market value of their outstanding shares is at $116.1 million. Aridis Pharmaceuticals (NASDAQ:ARDS) stock increased by 7.94% to $1.63. The company's market cap stands at $22.9 million. Scopus BioPharma (NASDAQ:SCPS) shares rose 5.92% to $1.61. The company's market cap s